Moderna ‘bivalent’ vaccine gets UK nod for adult booster jabs

THE UK’s drug regulator said on Monday (15) it had approved an updated Moderna vaccine against Covid-19 that targets the Omicron variant as well as the original form of the virus.

The Medicine and Healthcare products Regulatory Agency (MHRA) said it had approved the vaccine for adult booster doses “after it was found to meet the UK regulator’s standards of safety, quality and effectiveness”.

It was the first such “bivalent” Covid-19 vaccine to be approved by the British regulator.

The MHRA’s chief executive, June Raine, said data from a clinical trial had shown it prompted a “strong immune response” against the original virus and Omicron, and would provide a “sharpened tool in our armoury” as the virus kept evolving.

Stephane Bancel, Moderna’s CEO, said in a statement that the US biotech company was “delighted” by the decision, “the first authorization of an Omicroncontaining bivalent vaccine”.

While vaccines have helped lower hospitalisations and deaths from Covid, the current jabs are mainly aimed at the earlier strains of the disease. The World Health Organization warned in July that the pandemic was “nowhere near over”, due to the spread of Omicron subvariants and the lifting of control measures.

Half of the Moderna vaccine targets the original 2020 virus and half the Omicron variant, which is officially known as BA.1.

The MHRA said the vaccine was also found to generate a “good response” against two Omicron subvariants, BA.4 and BA.5, which have partly driven a wave of new cases of the disease in Europe and the United States.

The vaccine had the same “typically mild” side effects as the original Moderna jab, it added.

Moderna said in June its “bivalent” vaccine performed better against both Omicron and the original virus compared to its first Covid vaccine, called Spikevax.

The EU’s medicines watchdog said that month it had started to review the new shot.

It is also studying a rival adapted jab developed by Pfizer/ BioNTech, which may be approved this autumn.

The Pfizer/BioNTech jab is adapted for the BA.4 and BA.5 subvariants of the virus. They were first discovered in South Africa and spread rapidly despite high population immunity that was conferred by prior waves and vaccinations.

Like other Omicron subvariants, they tend to have a milder disease course as they settle less in the lungs and more in the upper nasal passages, causing symptoms such as fever, tiredness and loss of smell.